Intravenous peramivir given within 48 hours of influenza symptom onset was well tolerated, reduced fever, and shortened time to resumption of usual activities. To date, influenza treatments have ...

Elsewhere, BioCryst Pharmaceuticals, of Birmingham, Alabama, hopes to provide a third NA inhibitor, peramivir, which it is now positioning as an intravenous treatment for hospitalized patients ...

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare ...

Fortunately, most people with the flu feel better within about a week of their symptoms beginning. Nonetheless, the average ...

About RAPIVAB ® (peramivir injection) RAPIVAB ® (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza in patients six months and older who ...

Flu A is more common and can infect humans and animals, allowing it to cause widespread outbreaks. Flu B only affects humans, ...

with the U.S. Department of Health and Human Services awarding BioCryst a $69 million contract for procuring up to 95,625 doses of RAPIVAB (peramivir injection) for influenza treatment over five ...

But while flu is caused by influenza viruses only, a cold can be caused by more than 200 different viruses, according to Davis. These include rhinoviruses, enteroviruses, and (confusingly) ...

Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for an oral LTP therapyRESEARCH TRIANGLE PARK, N.C ...